Charmacy Pharmaceutical Co., Ltd.

SEHK:2289 주식 보고서

시가총액: HK$928.8m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Charmacy Pharmaceutical 관리

관리 기준 확인 4/4

Charmacy Pharmaceutical's CEO는 Chuanglong Yao, Mar2000 에 임명되었습니다 의 임기는 24.25 년입니다. 총 연간 보상은 CN¥ 728.07K, 87.4% 로 구성됩니다. 87.4% 급여 및 12.6% 보너스(회사 주식 및 옵션 포함). 는 HK$ 296.96M 가치에 해당하는 회사 주식의 31.97% 직접 소유합니다. 296.96M. 경영진과 이사회의 평균 재임 기간은 각각 2.2 년과 5.3 년입니다.

주요 정보

Chuanglong Yao

최고 경영자

CN¥728.1k

총 보상

CEO 급여 비율87.4%
CEO 임기24.3yrs
CEO 소유권32.0%
경영진 평균 재임 기간2.2yrs
이사회 평균 재임 기간5.3yrs

최근 관리 업데이트

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19
Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25
These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17
If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02
Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15
What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17
Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27
We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09
Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22
What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

CEO 보상 분석

Chuanglong Yao 의 보수는 Charmacy Pharmaceutical 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Dec 31 2023CN¥728kCN¥636k

CN¥51m

Sep 30 2023n/an/a

CN¥74m

Jun 30 2023n/an/a

CN¥96m

Mar 31 2023n/an/a

CN¥93m

Dec 31 2022CN¥732kCN¥638k

CN¥90m

Sep 30 2022n/an/a

CN¥54m

Jun 30 2022n/an/a

CN¥18m

Mar 31 2022n/an/a

CN¥20m

Dec 31 2021CN¥679kCN¥646k

CN¥23m

Sep 30 2021n/an/a

CN¥29m

Jun 30 2021n/an/a

CN¥36m

Mar 31 2021n/an/a

CN¥38m

Dec 31 2020CN¥685kCN¥649k

CN¥41m

Sep 30 2020n/an/a

CN¥35m

Jun 30 2020n/an/a

CN¥29m

Mar 31 2020n/an/a

CN¥34m

Dec 31 2019CN¥714kCN¥650k

CN¥40m

Sep 30 2019n/an/a

CN¥41m

Jun 30 2019n/an/a

CN¥42m

Mar 31 2019n/an/a

CN¥44m

Dec 31 2018CN¥715kCN¥649k

CN¥45m

Sep 30 2018n/an/a

CN¥46m

Jun 30 2018n/an/a

CN¥47m

Mar 31 2018n/an/a

CN¥46m

Dec 31 2017CN¥713kCN¥650k

CN¥45m

보상 대 시장: Chuanglong 의 총 보상 ($USD 100.29K ) Hong Kong 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 232.88K ).

보상과 수익: Chuanglong 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Chuanglong Yao (54 yo)

24.3yrs

테뉴어

CN¥728,071

보상

Mr. Chuanglong Yao has been Chief Executive Officer at Charmacy Pharmaceutical Co., Ltd. since March 2000 and serves as its Vice Chairman since May 31, 2023 and served as its Chairman since May 2015. Mr. Y...


리더십 팀

이름위치테뉴어보상소유권
Chuanglong Yao
CEO & Vice Chairman24.3yrsCN¥728.07k31.97%
CN¥ 297.0m
Hanzi Zhang
CFO & Executive Director2.2yrsCN¥385.49k데이터 없음
Yuyan Zheng
VP & Executive Director8.8yrsCN¥991.13k데이터 없음
Zhijie Lin
Chief Logistics Officer & CTOno dataCN¥188.00k데이터 없음
Wai Ling Wong
Joint Company Secretary2.2yrs데이터 없음데이터 없음
Jiexi Yao
Joint Company Secretary2.2yrs데이터 없음데이터 없음

2.2yrs

평균 재임 기간

45yo

평균 연령

경험이 풍부한 관리: 2289 의 관리팀은 경험 ( 2.2 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Chuanglong Yao
CEO & Vice Chairman24.3yrsCN¥728.07k31.97%
CN¥ 297.0m
Hanzi Zhang
CFO & Executive Director1.9yrsCN¥385.49k데이터 없음
Yuyan Zheng
VP & Executive Director9.1yrsCN¥991.13k데이터 없음
Chi Wai Wan
Independent Non-Executive Director8.5yrsCN¥144.00k데이터 없음
Jian Guan
Independent Non-Executive Director8.5yrsCN¥50.00k데이터 없음
Ling Zhang
Independent Supervisor9.1yrs데이터 없음데이터 없음
Xiyue Zheng
Employee Representative Supervisor9.1yrs데이터 없음데이터 없음
Hanguo Li
Independent Non-Executive Director1.1yrsCN¥29.30k데이터 없음
Zheng Fu
Non-Executive Director1.9yrs데이터 없음데이터 없음
Jingbin Yan
Non-Executive Chairman2yrs데이터 없음데이터 없음
Fei Xu
Non-Executive Director1.1yrs데이터 없음데이터 없음
Minghong Zhu
Chairman of the Board of Supervisors1.1yrs데이터 없음데이터 없음

5.3yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 이사회: 2289 의 이사회경험(평균 재직 기간 5.3 년)으로 간주됩니다.